Pharmaceuticals

Global Central Nervous System Therapeutics Market 2025–2029: Competitive Insights and Opportunities

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Central Nervous System Therapeutics Industry Expected To Reach By 2029, Starting From 2025 Levels?

The central nervous system therapeutics market size has seen robust expansion in recent years. It is forecast to grow from $123.53 billion in 2024 to $134.99 billion in 2025, representing a compound annual growth rate (CAGR) of 9.3%. The market’s past growth can be ascribed to an increase in neurological disorders, a rise in mental health awareness, an increase in research and development activities, a rise in demand for personalized medicine, and an increase in trade agreements.

The central nervous system therapeutics market is projected to experience substantial expansion over the upcoming years. This market is set to reach $190.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.9%. This anticipated growth is driven by factors such as the rising incidence of CNS disorders, a heightened emphasis on therapeutic development, the growing occurrence of conditions like Alzheimer’s, an expanding elderly demographic, and a greater need for efficacious treatments. Key trends expected during this period encompass artificial intelligence applications in diagnostics, progress in antidepressant drug development, innovations in drug delivery systems, advancements within neurology, and the identification of biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

Which Drivers Are Shaping The Central Nervous System Therapeutics Industry’s Market Share?

The rising occurrence of mental health disorders is anticipated to propel the growth of the central nervous system therapeutics market moving forward. These conditions encompass a wide spectrum of issues that impact an individual’s thought processes, emotions, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The increasing prevalence of mental health disorders stems from heightened exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics aid in treating mental health disorders by targeting specific brain chemicals and neural pathways involved in mood, behavior, and cognition. For example, in December 2025, a report from the UK-based Bristol City Council indicated that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022/23, marking a 6.0% rise from 2021/22. Consequently, the increasing prevalence of mental health disorders is a key driver for the central nervous system therapeutics market’s expansion.

What Are The Major Segments Identified In The Central Nervous System Therapeutics Market?

The central nervous system therapeutics market covered in this report is segmented

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief, Topical Agents

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Which Trends Are Impacting The Central Nervous System Therapeutics Market?

Leading companies in the central nervous system therapeutics market are prioritizing the development of innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, commonly adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a biotechnology company based in France, introduced coAAV CSF 01, a novel adeno-associated virus (AAV) designed for central nervous system (CNS) delivery using their proprietary ALIGATER platform. It demonstrated significantly improved transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, expression levels equivalent to AAV9 were attained at merely one-fifth of the dose, showcasing its superior potency. Additionally, the vector displayed substantially reduced off-target expression in peripheral organs such as the liver, while sustaining a favorable safety profile, including preserved peripheral nerve integrity. These results highlight the vector’s potential to enhance CNS gene therapy outcomes with greater precision and reduced systemic risk.

Who Are The Key Multinational Companies Dominating The Central Nervous System Therapeutics Market?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

How Does The Central Nervous System Therapeutics Market Perform Across Key Geographic Regions?

North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Central Nervous System Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2025, By The Business Research Company

Coronavirus Current Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insurance-global-market-report

Critical Illness Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/critical-illness-insurance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795